Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (16061)	9/12/2002 8:29:50 PM
From: tom pope	Read Replies (1) \| Respond to of 17367

Aha, I see you have the actual BGEN release, which wasn't up when I posted the snippet. What it really means? Beats me, but here's the full BGEN release. Cacaito, do you have insights? CAMBRIDGE, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Biogen, Inc. (Nasdaq: BGEN - News) today announced that the Food and Drug Administration (FDA) has committed to complete the review of its AMEVIVE® (alefacept) application within six months. After review of the information Biogen submitted to reply to FDA's Complete Response Letter, FDA determined it was a class 2 resubmission. Under FDA guidelines, this commits the Agency to complete the review within six months. Biogen is now one step closer toward the approval of AMEVIVE for the treatment of moderate-to-severe chronic plaque psoriasis.